Saturday, 21 November 2026
M
Meridian Globe
Live briefing
[Editorial] Multiple sclerosis: beyond controlling relapses— 柳叶刀 Lancet[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?— 柳叶刀 Lancet[Comment] Expanding the post-EGFR TKI landscape with antibody–drug conjugates— 柳叶刀 Lancet[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer— 柳叶刀 Lancet[Comment] Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother— 柳叶刀 Lancet[Comment] Offline: A manifesto for protecting public health— 柳叶刀 Lancet[World Report] Türkiye's coal industry draws criticism— 柳叶刀 Lancet[World Report] Research Focus: Te Poutoko Ora a Kiwa (Centre for Pacific and Global Health)— 柳叶刀 Lancet[Editorial] Multiple sclerosis: beyond controlling relapses— 柳叶刀 Lancet[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?— 柳叶刀 Lancet[Comment] Expanding the post-EGFR TKI landscape with antibody–drug conjugates— 柳叶刀 Lancet[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer— 柳叶刀 Lancet[Comment] Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother— 柳叶刀 Lancet[Comment] Offline: A manifesto for protecting public health— 柳叶刀 Lancet[World Report] Türkiye's coal industry draws criticism— 柳叶刀 Lancet[World Report] Research Focus: Te Poutoko Ora a Kiwa (Centre for Pacific and Global Health)— 柳叶刀 Lancet

Mexico September Retail Sales Fall 0.3%

Source Rio Times 里约时报5h ago
Summary

Mexico's retail sales fell 0.3% in September as forecast, but yearly growth slowed to 2.2%, below the 2.7% consensus forecast. The post Mexico September Retail…

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
World
Region
Brazil
Language
English
Item ID
world-46959075

Comments 0 comments

No comments yet. Be the first.

Mexico September Retail Sales Fall 0.3% · Meridian Globe